U.S. COMPANY FILING
VERTEX PHARMACEUTICALS INC / MA — Form 10-Q filed 2025-11-04
Filing text preview
Vertex Pharmaceuticals reported Q3 2025 total revenues of $3.08 billion, up 11% YoY, driven by TRIKAFTA and ALYFTREK. Net income was $1.08 billion, up 3.6%. For nine months, revenues were $8.81 billion with net income of $2.76 billion, a turnaround from a loss. The company advanced povetacicept partnerships and recorded a $379 million impairment for VX-264.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record